Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

Recruiting now · Phase 2

Conditions studied: Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease

In brief

In France, since the reimbursement of Lutathera®, this treatment is allowed for retreatment if patients still fulfill the criteria of its indication and 4 news cycles could be proposed. However, clinical practices are heterogeneous regarding the number of new cycles and most teams perform only two additional cycles (every 8 weeks). Therefore, the coordinator propose to evaluate the efficacy of two additional cycle of Lutathera® versus active surveillance in patients already retreated with two cycles Lutathera® for a new progression of intestinal neuroendocrine tumor and who previously received the 4 cycles of treatment with a clinical benefit.

Key facts

Study ID

NCT04954820

Run by

Institut du Cancer de Montpellier - Val d'Aurelle

People needed

146

Starts

2021-10-18

Expected to finish

2033-10-01

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years,
• Histologically proven intestinal G1 or G2 neuroendocrine tumors (NET),
• Patient previously treated with 4 cycles of Lutathera® (defined as "First PRRT"),
• Disease control after "First PRRT" ≥ 12 months,
• Patient presenting a progression of disease (clinic, biologic and/or radiologic) after a first PRRT,
• Decision of retreatment with Lutathera® (defined as "Second PRRT") validated by RENATEN and/or multidisciplinary tumor board and in the scope of the French reimbursement process,
• ECOG performance status 0-2,
• Life expectancy ≥ 6 months as prognosticated by the physician,
• Somatostatin receptor imaging positive imaging (SSTRi+) disease within 4 months prior to inclusion : (may be PET imaging (68Ga-based SSTR analogues) or scintigraphy imaging: 111In-pentetreotide or 99mTc-octreotide. At least 90% of lesions must be positive for SSTRi with a significant uptake (>= liver of surrounding tissue),
• Measurable disease per RECIST 1.1 (Appendix 1), on CT/MRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter, and ≥ 2 radiological tumors lesions in total,
• Adequate bone marrow reserve (Hb > 8 g/dl, neutrophils ≥ 1500/mm³ and platelets ≥ 80 000/mm³),
• Negative pregnancy test in women of childbearing potential (the β-HCG dosage must be ≤ 4 days before inclusion). Women who have no reproductive potential are postmenopausal women or women who have had permanent sterilization, eg. tubal occlusion, hysterectomy, bilateral salpingectomy),
• Effective contraception in men or women of childbearing or pre-menopausal age and up to a minimum of 6 months following the end of treatment,
• Patient´s signed written informed consent,
• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,
• Affiliation to the French Social Security System

You may not qualify if…

• Patient who did not respond (no CR, PR or SD) to "first PRRT".
• Radiological progression after two cycles of "Second PRRT" according to RECIST version 1.1,
• Grade 4 hematotoxicity and/or nephrotoxicity during the initial PRRT, or unresolved AEs categorized as Grade 2 or higher (as per Common Terminology Criteria for Adverse Events (CTCAE v5.0) from previous PRRT cycles or any other therapy for NET, excluding alopecia and peripheral neuropathy,
• Pancreatic NET,
• NeuroEndocrine Carcinoma,
• Prior external beam radiation therapy to more than 25% of the bone marrow,
• Severe renal (estimated Glomerular Filtration Rate (GFR) according to Modification of Diet in Renal Disease (MDRD) < 40 mL/min or nephrotic syndrome) or hepatic insufficiency (Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) > 2.5 x ULN or ALT/AST > 5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin > 2.5 x ULN),
• Serum albumin < 3.0 g/dL unless prothrombin time is within the normal range,
• Uncontrolled diabetes mellitus as defined by a fasting blood glucose above 2 ULN,
• Uncontrolled decompensated heart failure, myocardial infarction uncontrolled, stroke, pulmonary embolism or revascularization procedure, unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the last 12 months,
• Hypertension that cannot be controlled despite medications (≥ 160/95 mmHg despite optimal medical therapy)
• Brain metastases (unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrolment in the study. Patients with a history of brain metastases must have a head CT scan with contrast or MRI to document stable disease prior to enrolment in the study),
• Pregnancy or breast feeding,
• Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results,
• Known hypersensitivity to any of the study drugs, study drug classes, or any constituent of the products,
• Concomitant participation or participation within the last 30 days in another clinical trial,
• History of other solid tumor in 5 years before the inclusion excepted of cancer in situ of the cervix and skin cancer (basal or squamous cell) treated and controlled.
• Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study.

Where it is running

• Institut Gustave Roussy — Villejuif, France (enrolling)
• Institut Bergonié — Bordeaux, France (enrolling)
• CHRU Morvan — Brest, France (enrolling)
• Hospices civils de LYON - GHE — Bron, France (enrolling)
• Centre François Baclesse — Caen, France (enrolling)
• CH Métropole de Savoie — Chambéry, France (enrolling)
• Centre Jean Perrin — Clermont-Ferrand, France (enrolling)
• Hopital Beaujon — Clichy, France (enrolling)
• CHU de DIJON — Dijon, France (enrolling)
• CHU Grenoble Alpes (CHUGA) — La Tronche, France (enrolling)
• CHRU Lille — Lille, France (enrolling)
• Centre léon bérard — Lyon, France (enrolling)
• Institut Paoli Calmettes — Marseille, France (enrolling)
• Hôpital de la Timone — Marseille, France (enrolling)
• ICM Val d'Aurelle — Montpellier, France (enrolling)
• CHU Nantes — Nantes, France (enrolling)
• Centre Antoine Lacassagne — Nice, France (enrolling)
• Hôpital Pitié Salpétrière — Paris, France (enrolling)
• Hôpital Cochin — Paris, France (enrolling)
• Hôpital Haut-Lévêque — Pessac, France (enrolling)
• Centre Henri Becquerel — Rouen, France (enrolling)
• Institut de Cancérologie de l'Ouest Site d'Angers — Angers, France (enrolling)
• CHU ST Etienne — Saint-Etienne, France (enrolling)
• Institut de Cancérologie de l'Ouest — Saint-Herblain, France (enrolling)
• Hôpitaux Universitaires de Strasbourg — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.